Evidence map›Paper›PMID 33127911›Full record

ArticleNature communications2020

Genomic surveillance of COVID-19 cases in Beijing.

Pengcheng Du, Nan Ding, Jiarui Li, Fujie Zhang, Qi Wang, Zhihai Chen, Chuan Song, Kai Han, Wen Xie, Jingyuan Liu and 18 more

Abstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Pengcheng DuBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Nan DingBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.ORCID 0000-0002-1045-1695
Jiarui LiBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Fujie ZhangBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.ORCID 0000-0001-6386-9879
Qi WangBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Zhihai ChenBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.ORCID 0000-0001-6481-4781
Chuan SongBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Kai HanBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Wen XieBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Jingyuan LiuBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Linghang WangBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Lirong WeiBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Shanfang MaBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Mingxi HuaBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Fengting YuBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Lin WangMGI, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Wei WangMGI, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Kang AnBGI-Genomics, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China.
Jianjun ChenCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China.ORCID 0000-0002-2966-2388
Haizhou LiuNational Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China.ORCID 0000-0002-4727-088X
Guiju GaoBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Sa WangBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Yanyi HuangBiomedical Pioneering Innovation Center (BIOPIC), Beijing Advanced Innovation Center for Genomics (ICG), College of Chemistry and Molecular Engineering, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, People's Republic of China.ORCID 0000-0002-7297-1266
Angela R WuDivision of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, SAR, People's Republic of China.ORCID 0000-0002-3531-4830
Jianbin WangSchool of Life Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology (ICSB), Chinese Institute for Brain Research (CIBR), Tsinghua University, Beijing, 100084, People's Republic of China. jianbinwang@tsinghua.edu.cn.ORCID 0000-0001-6725-7925
Di LiuCAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China. liud@im.ac.cn.ORCID 0000-0003-3693-2726
Hui ZengBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China. zenghui@ccmu.edu.cn.ORCID 0000-0002-7456-6061
Chen ChenBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China. chenchen1@ccmu.edu.cn.ORCID 0000-0003-1765-8899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of SARS-CoV-2 in Beijing before May, 2020 resulted from transmission following both domestic and global importation of cases. Here we present genomic surveillance data on 102 imported cases, which account for 17.2% of the total cases in Beijing. Our data suggest that all of the cases in Beijing can be broadly classified into one of three groups: Wuhan exposure, local transmission and overseas imports. We classify all sequenced genomes into seven clusters based on representative high-frequency single nucleotide polymorphisms (SNPs). Genomic comparisons reveal higher genomic diversity in the imported group compared to both the Wuhan exposure and local transmission groups, indicating continuous genomic evolution during global transmission. The imported group show region-specific SNPs, while the intra-host single nucleotide variations present as random features, and show no significant differences among groups. Epidemiological data suggest that detection of cases at immigration with mandatory quarantine may be an effective way to prevent recurring outbreaks triggered by imported cases. Notably, we also identify a set of novel indels. Our data imply that SARS-CoV-2 genomes may have high mutational tolerance.

Indexed as

AdultBeijingBetacoronavirusCoronavirus InfectionsCOVID-19FemaleGenome, ViralGenomicsGenotypeHumansMaleMiddle AgedMutationPandemicsPhylogenyPneumonia, Viral

Identifiers

PMID33127911
PMCPMC7603498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.